MASLD & Gut–Metabolic Health
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now one of the most common chronic liver diseases worldwide, and the gut microbiome has emerged as an important influence on metabolism, inflammation and disease risk.
The liver and gut sit at the heart of metabolism.
MASLD is closely associated with obesity, insulin resistance, Type 2 diabetes and dyslipidaemia. It can progress from simple steatosis to steatohepatitis (MASH), fibrosis, cirrhosis and liver cancer — and people with MASLD also carry a significantly increased cardiovascular risk.
The gut–liver axis links these conditions. The gut microbiome influences energy harvest, bile-acid metabolism, intestinal permeability and systemic inflammation, contributing to obesity, insulin resistance and liver disease.
IMACH aims to improve awareness, early detection and multidisciplinary management of MASLD, while following the developing science of the microbiome and translating reliable evidence into practical nutritional and clinical guidance.
Key areas of scientific focus
MASLD
- MASLD nomenclature and diagnostic criteria
- Screening of at-risk populations: diabetes, obesity
- Non-invasive fibrosis assessment: FIB-4, elastography
- MASH and progression to cirrhosis
- Cardiovascular risk in MASLD
- Emerging pharmacological therapies
Gut microbiome
- Gut microbiome composition and metabolic function
- Gut–liver and gut–brain axes
- Microbiome in obesity and Type 2 diabetes
- Diet, fibre and microbial diversity
- Probiotics, prebiotics and synbiotics: the evidence
- Effects of medicines on the microbiome
Management
- Weight loss and lifestyle intervention
- Nutritional strategies for liver health
- Role of metabolic medicines in MASLD
- Alcohol and MASLD
- Referral pathways to hepatology
- Long-term monitoring
Clinical challenges we address
Silent progression
MASLD is usually asymptomatic until advanced fibrosis develops.
Low screening rates
Many people with diabetes and obesity are never assessed for liver fibrosis.
Normal enzymes
Normal liver tests do not exclude significant disease.
Limited therapies
Lifestyle change remains the foundation while new drugs emerge.
Microbiome hype
Commercial claims often outpace scientific evidence.
Cardiovascular neglect
The leading cause of death in MASLD is cardiovascular disease, not liver failure.
Translating evidence into everyday care
IMACH promotes simple, stepwise assessment of liver fibrosis in primary and metabolic care, combined with weight-centred treatment and cardiovascular risk management.
A practical MASLD pathway:
| Care stage | Focus for clinicians |
|---|---|
| Identify risk | Diabetes, obesity, metabolic syndrome, raised liver enzymes or fatty liver on imaging. |
| First-line test | Calculate FIB-4 from routine bloods. |
| Second-line test | Elastography or other non-invasive tests for intermediate/high scores. |
| Manage | Weight loss, nutrition, activity, alcohol reduction and metabolic therapy. |
| Refer & monitor | Hepatology referral for advanced fibrosis; regular reassessment. |
IMACH programmes in this area
MASLD in practice workshops
Screening and non-invasive assessment for non-hepatologists.
Hepatology–diabetology forums
Joint care of metabolic liver disease.
Microbiome science updates
Critical review of emerging research.
Liver nutrition modules
Dietary patterns that support liver health.
Case discussions
Complex MASLD with diabetes, obesity and CVD.
Awareness initiatives
Patient education on fatty liver.
Who this area brings together
Metabolic liver disease spans hepatology, gastroenterology, endocrinology, cardiology and nutrition.
Questions we explore
- Who should be screened for MASLD and how?
- How can primary care identify advanced fibrosis early?
- What degree of weight loss benefits the liver?
- What does current evidence actually support on probiotics?
- How should cardiovascular risk be managed in MASLD?
Frequently asked questions
What happened to NAFLD?
The term NAFLD has been replaced internationally by MASLD to emphasise the metabolic cause and reduce stigma.
Why combine MASLD and the gut microbiome?
Both are linked through the gut–liver axis and share the same metabolic drivers.
Does IMACH endorse probiotic products?
No. IMACH reviews the evidence and does not endorse commercial products.
This page is intended for healthcare professionals and is educational in nature. It does not constitute medical advice or treatment recommendations for individual patients. Clinical decisions should follow current guidelines, local regulations and individual patient assessment.
Contribute to liver and gut–metabolic care at IMACH.
Join as a member, faculty or research collaborator in this therapy area.